Lisata unit Marea to present Phase 2b TYDAL data on MAR001 at AHA Scientific Sessions 2026
LSTA•Lisata announced that Phase 2b TYDAL trial data for MAR001 will be presented on Nov. 9, 2026, at the AHA Scientific Sessions in Chicago.
1. Presentation scheduled
The late-breaking presentation will share results from the Phase 2b TYDAL trial of MAR001. The drug targets ANGPTL4, aiming to lower triglycerides and improve metabolic health in adults with elevated triglycerides and remnant cholesterol. MAR005, a longer-acting version, is the planned Phase 3 candidate for severe hypertriglyceridemia.
